Who founded GENEOS Therapeutics?

GENEOS Therapeutics was founded by Niranjan Y. Sardesai.

Who are GENEOS Therapeutics's investors?

GENEOS Therapeutics's investors include 3B Future Health Fund.

How much funding has GENEOS Therapeutics raised?

GENEOS Therapeutics has disclosed $37.1M raised across 4 rounds.

Where is GENEOS Therapeutics headquartered?

GENEOS Therapeutics is headquartered in Plymouth Meeting, US.

GENEOS Therapeutics

Plymouth Meeting, US · Delaware corporation · 1 known investors

Biotech

Founders & leadership

Niranjan Y. SardesaiFounder

Laurent HumeauNamed on SEC filing

James EadieNamed on SEC filing

Samuel BroderNamed on SEC filing

Sangwoo LeeNamed on SEC filing

Casey CunninghamNamed on SEC filing

Ted FjallmanNamed on SEC filing

Investors · 1

3B Future Health FundMonaco · $12M

Reported raises · per SEC filings

Form D private placements

$37.1M disclosed across 4 rounds · 2019–2023

▶$5MraisedApr 2023 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Laurent HumeauDirector
James EadieDirector
Niranjan Y. SardesaiExecutive Officer, Director
Samuel BroderDirector
Sangwoo LeeDirector
Casey CunninghamDirector
Ted FjallmanDirector

Offering amount: $10M
Amount sold: $5M
First sale: Mar 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$17.2MraisedMar 2022 · 9 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joseph KimDirector
Samuel BroderDirector
Sangwoo LeeDirector
Ted FjallmanDirector
Niranjan SardesaiExecutive Officer, Director
Eadie JamesDirector
Casey CunninghamDirector

Offering amount: $25M
Amount sold: $17.2M
First sale: Mar 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10.4MraisedNov 2020 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

James EadieDirector
J. Joseph KimDirector
Casey CunninghamDirector
Samuel BroderDirector
Niranjan Y. SardesaiExecutive Officer, Director
Sangwoo LeeDirector

Offering amount: $12M
Amount sold: $10.4M
First sale: Nov 2020
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$4.5MraisedFeb 2019 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

J. Joseph KimDirector
Casey CunninghamDirector
James EadieDirector
Samuel Dr. BroderDirector
Niranjan Y. SardesaiExecutive Officer, Director

Offering amount: $10.5M
Amount sold: $4.5M
Sales commissions: $50K
Placement agents: CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets), M.M. Dillon & Co., LLC, CIM Securities, LLC (Brookline Capital Markets), CIM Securities, LLC (Brookline Capital Markets)
First sale: Feb 2019
Incorporated: Corporation, Delaware, 2016
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

Who founded GENEOS Therapeutics?: GENEOS Therapeutics was founded by Niranjan Y. Sardesai.
Who are GENEOS Therapeutics's investors?: GENEOS Therapeutics's investors include 3B Future Health Fund.
How much funding has GENEOS Therapeutics raised?: GENEOS Therapeutics has disclosed $37.1M raised across 4 rounds.
Where is GENEOS Therapeutics headquartered?: GENEOS Therapeutics is headquartered in Plymouth Meeting, US.